eicosapentaenoic acid/悪性腫瘍

FIELD OF THE INVENTION The invention relates generally to the fields of molecular genetics, molecular biology, and oncology. BACKGROUND Leukemia is a highly prevalent disease that signifies uncontrolled production of white blood cells. Currently, there is no cure for leukemia. Current therapies of

FIELD OF THE INVENTION The invention relates generally to the fields of molecular genetics, molecular biology, and oncology. BACKGROUND Leukemia is a highly prevalent disease that signifies uncontrolled production of white blood cells. Currently, there is no cure for leukemia. Current therapies of

FIELD OF THE INVENTION The invention relates generally to the fields of molecular genetics, molecular biology, and oncology. BACKGROUND Leukemia is a highly prevalent disease that signifies uncontrolled production of white blood cells. Currently, there is no cure for leukemia. Current therapies of

FIELD OF INVENTION The invention relates to iron-containing compositions and methods for the treatment of cancer. PUBLISHED PATENT APPLICATIONS AND GENERAL LITERATURE In previous Patent Applications of the inventor the role of essential fatty acids in cancer, and particularly of gamma-linolenic acid

FIELD OF INVENTION The invention relates to iron-containing compositions and methods for the treatment of cancer. PUBLISHED PATENT APPLICATIONS AND GENERAL LITERATURE In previous Patent Applications of the inventor the role of essential fatty acids in cancer, and particularly of gamma-linolenic acid

FIELD The invention relates to nutraceutical and pharmaceutical compositions, more in particular compositions that can improve membrane composition and functioning of cells and through this the general cell functioning. BACKGROUND Membranes in living cells are known to have many important functions.

FIELD The invention relates to nutraceutical and pharmaceutical compositions, more in particular compositions that can improve membrane composition and functioning of cells and through this the general cell functioning. BACKGROUND Membranes in living cells are known to have many important functions.

FIELD The invention relates to nutraceutical and pharmaceutical compositions, more in particular compositions that can improve membrane composition and functioning of cells and through this the general cell functioning. BACKGROUND Membranes in living cells are known to have many important functions.

FIELD The invention relates to nutraceutical and pharmaceutical compositions, more in particular compositions that can improve membrane composition and functioning of cells and through this the general cell functioning. BACKGROUND Membranes in living cells are known to have many important functions.

FIELD The invention relates to nutraceutical and pharmaceutical compositions, more in particular compositions that can improve membrane composition and functioning of cells and through this the general cell functioning. BACKGROUND Membranes in living cells are known to have many important functions.

CROSS REFERENCE TO RELATED APPLICATIONS This application is a U.S. national stage application of International Application No. PCT/EP2015/051657, filed on Jan. 28, 2015, which claims priority to European Application No. 14152785.3, filed on Jan. 28, 2014. The contents of these previously filed

The present invention relates to an enteral nutritional supplement for persons with cancer who are not currently undergoing radiation therapy and/or chemotherapy. Cancer patients typically undergo intermittent periods of chemotherapy and/or radiation therapy during which their nutritional needs are

The invention concerns a foodstuff which at continued ingestion has as prophylactic and/or healing effect for prevention and/or healing of certain diseases, mainly diseases of civilization caused by an unhealthy way of nutrition, abuse of alcohol and nicotine and by an increasing environmental

CROSS REFERENCE TO RELATED APPLICATIONS This application is a U.S. national stage application of International Application No. PCT/EP2015/051656, filed on Jan. 28, 2015, which claims priority to European Application No. 14152786.1, filed on Jan. 28, 2014. The contents of these previously filed

TECHNICAL FIELD This invention relates to methods for reducing inflammation and angiogenesis, e.g., reducing or reversing angiogenesis, in a subject by administering a pharmaceutical composition comprising one or more epoxymetabolites derived from omega-3 long chain polyunsaturated fatty acids